| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_59e1d955a7b1560dc68cf7fd800e8fac
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_135fae6b5d8e5096542acbafe57c9316 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-75
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-31
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-4846
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y304-21022 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-36 |
| filingDate |
2018-03-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_57930f445c55e183a0d05ab96b9bb5cd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6d4adeb90aaf85268ef755d1166390ba
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_21ae5f60d3c3ddcb0bcfa35602a33b69 |
| publicationDate |
2019-11-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-110461358-A |
| titleOfInvention |
Pharmaceutical composition for preventing and/or treating abnormality of coagulation factor IX, comprising a multispecific antigen-binding molecule that replaces the function of coagulation factor VIII |
| abstract |
The present inventors examined the procoagulant activity of multispecific antigen binding molecules functionally substituted for FVIII using blood and plasma from patients with FIX disorders. The results show that, due to its procoagulant activity, multispecific antigen-binding molecules functionally replacing FVIII can be used not only for the prevention and/or treatment of hemophilia A, acquired hemophilia A, von Willebrand disease caused by FVIII dysfunction. The method of bleeding in febrile disease and hemophilia C can also be used as a method of preventing and/or treating bleeding in FIX disorders. Furthermore, the effect of FIX preparations can be enhanced by using it in combination with a multispecific antigen-binding molecule that is functionally substituted for FVIII, suggesting that the combined use is promising as a combination therapy showing stable hemostatic effects. |
| priorityDate |
2017-03-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |